AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05823623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Study NCT05823623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Study NCT05823623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vinorelbine Tartrate
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Study NCT05821842 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sonu
Description: Acoustic energy delivery
Study NCT05821842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonu
Description: Acoustic energy delivery
Study NCT04250623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care product (gel)
Description: hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
Study NCT05873205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: All participants enrolled on the study will receive isatuximab intravenously as a single agent
Study NCT05850962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualised MAP target
Description: The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
Study NCT04637100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile or tablet-based gaming applications
Description: Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
Study NCT06035744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-617
Description: Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
Study NCT06035744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized IgG4 anti-PD-1 monoclonal antibody
Study NCT05173415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirius Pintution
Description: The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
Study NCT05173415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HydroMARK (C) Clip
Description: The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
Study NCT04637100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke-related educational videos
Description: Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
Study NCT04678349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PHGG
Description: Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
Study NCT04678349 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional care
Description: follow low fibre diet and anti-diarrhea drugs
Study NCT05528068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised lifestyle intervention
Description: Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
Study NCT05528068 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: healthy lifestyle education
Description: Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
Study NCT05755347 — intervention group
Intervention type: OTHER
Intervention: General health survey questionnaires
Description: Patient-reported outcome survey will be offered at baseline.
Study NCT05755347 — intervention group
Intervention type: OTHER
Intervention: PROMIS Cancer Function Brief 3D profile questionnaires
Description: Patient-reported outcome survey will be offered at baseline.
Study NCT05755347 — intervention group
Intervention type: OTHER
Intervention: FACT-G questionnaires
Description: Patient-reported outcome survey will be offered at baseline.
Study NCT05755347 — intervention group
Intervention type: OTHER
Intervention: Godin Leisure-Time Exercise Questionnaire
Description: Patient-reported outcome survey will be offered at baseline.
Study NCT05755347 — intervention group
Intervention type: OTHER
Intervention: REAP-S questionnaires
Description: Patient-reported outcome survey will be offered at baseline.
Study NCT06359028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: Toothpaste containing 0.454 % weight/weight (w/w) SnF2
Study NCT06359028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest cavity protection toothpaste
Description: Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
Study NCT04557475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Two tablets daily with dinner
Study NCT06402149 — intervention group
Intervention type: OTHER
Intervention: dexamethasone
Description: Use of dexamethasone in infraclavicular block
Study NCT05647928 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-1mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-2.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-7.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
Study NCT05256719 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-10mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
Study NCT06632119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: high-intensity laser therapy (HILT) machine, ASA laser
Study NCT06632119 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-HILT
Description: Sham-HILT, HILT machine without laser release
Study NCT06634264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Oral Appliance
Description: Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
Study NCT05326282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi-parametric ultrasound
Description: Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
Study NCT05055583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab in Combination With Platinum-based Chemotherapy
Description: Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
Study NCT05055583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment stage
Description: After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
Study NCT05055583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment stage
Description: Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
Study NCT05263310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prepare for Your Diabetes Care
Description: Educational video and Action Plan handout
Study NCT05263310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Control arm patients will continue with usual care
Study NCT06473012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Caregivers of Older Adults
Description: Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.
Study NCT06473012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention for Caregivers of Older Adults
Description: The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
Study NCT05336032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food (rice)
Description: Cooked rice with 75 gm carbohydrate
Study NCT05336032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (rice)
Description: Cooked rice with 75 gm carbohydrate
Study NCT05659693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital literacy education specific to menopause
Description: Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
Study NCT06192056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RNT Focused Web- Based Self-Help Program
Description: This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
Study NCT05931653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physical therapy
Description: • Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
Study NCT05931653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training along with and Multimodal Physical therapy
Description: * Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s.
Study NCT04429308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Description: Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
Study NCT04429308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Peels
Description: Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
Study NCT05248165 — intervention group
Intervention type: DEVICE
Intervention: PCI
Description: Percutaneous coronary intervention
Study NCT06287138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
Study NCT05716425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
Study NCT05716425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STI-1558 placebo
Description: STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
Study NCT06392542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Selves
Description: Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
Study NCT06412783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test
Description: performing blood tests on the participants for specific markers.
Study NCT05800067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axi-cel
Description: Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
Study NCT05314192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for MIP-1 alpha
Study NCT05314192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for IL-6
Study NCT05754060 — intervention group
Intervention type: OTHER
Intervention: Saint-Louis Lille Battery (SSLIB)
Description: Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)
Study NCT05004974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered every 3 weeks (200mg, IV).
Study NCT05004974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
Study NCT06508372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical thymoquinone Ointment
Description: One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
Study NCT06508372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical placebo ointment
Description: In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
Study NCT05551975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product
Description: Fed from Study Day 1
Study NCT05551975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product 1
Description: Fed from Study Day 1
Study NCT05551975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product 2
Description: Fed from Study Day 1
Study NCT04988282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Tablet
Description: Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
Study NCT04988282 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone Tablet
Description: Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks